HIF1A and steatosis: The important therapeutic action at the transition from steatosis to SH will be to revert mitochondrial damage (e.g., by administration of mitochondrially targeted antioxidants/SDH uncouplers [222,223,224,225], which have already been used in clinical trials [46]), improve mitochondrial quality control [226], and prevent pseudohypoxia (e.g., by Hif-1 and Hif-2 inhibitors).